<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00030485</url>
  </required_header>
  <id_info>
    <org_study_id>I148</org_study_id>
    <secondary_id>CAN-NCIC-IND148</secondary_id>
    <secondary_id>NCI-NCIC-148</secondary_id>
    <secondary_id>CDR0000069169</secondary_id>
    <nct_id>NCT00030485</nct_id>
  </id_info>
  <brief_title>Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer</brief_title>
  <official_title>A Phase II Study of OSI-774 (NSC 718781) in Patients With Locally Advanced and/or Metastatic Carcinoma of the Endometrium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor&#xD;
      cells and slow the growth of the tumor.&#xD;
&#xD;
      PURPOSE: Phase II trial to determine the effectiveness of erlotinib in treating patients who&#xD;
      have locally advanced and/or metastatic endometrial cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of erlotinib, in terms of response rate and duration of stable&#xD;
           disease, in patients with locally advanced and/or metastatic carcinoma of the&#xD;
           endometrium.&#xD;
&#xD;
        -  Determine the toxicity of this drug in these patients.&#xD;
&#xD;
        -  Determine the time to progression and duration of response in patients treated with this&#xD;
           drug.&#xD;
&#xD;
        -  Correlate objective tumor response with levels of epidermal growth factor receptor&#xD;
           expression in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral erlotinib once daily. Courses repeat every 28 days in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed at 4 weeks. Patients with complete or partial response or stable&#xD;
      disease are also followed every 3 months until relapse or death.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15-30 patients will be accrued for this study within 12-18&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Endometrial Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic and/or locally advanced adenocarcinoma or&#xD;
             adenosquamous carcinoma of the endometrium&#xD;
&#xD;
               -  Incurable by standard therapies&#xD;
&#xD;
          -  Clinically and/or radiologically documented disease with at least 1 unidimensionally&#xD;
             measurable site&#xD;
&#xD;
               -  At least 20 mm by x-ray, physical exam, or CT scan OR&#xD;
&#xD;
               -  At least 10 mm by spiral CT scan&#xD;
&#xD;
               -  Bone metastases considered nonmeasurable&#xD;
&#xD;
          -  Tumor tissue from primary tumor available for assessing epidermal growth factor&#xD;
             receptor (EGFR) status&#xD;
&#xD;
          -  No uterine sarcomas (leiomyosarcoma), mixed mullerian tumors, and/or adenosarcomas&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
          -  Absolute granulocyte count at least 1,500/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than upper limit of normal (ULN)&#xD;
&#xD;
          -  AST/ALT no greater than 2.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Gastrointestinal:&#xD;
&#xD;
          -  No gastrointestinal (GI) tract disease that would preclude ability to take oral&#xD;
             medication&#xD;
&#xD;
          -  No requirement for IV alimentation&#xD;
&#xD;
          -  No uncontrolled inflammatory GI disease (e.g., Crohn's disease or ulcerative colitis)&#xD;
&#xD;
          -  No active peptic ulcer disease&#xD;
&#xD;
        Ophthalmic:&#xD;
&#xD;
          -  No significant ophthalmologic abnormalities, including any of the following:&#xD;
&#xD;
               -  Prior severe dry eye syndrome, Sjogren's syndrome, or keratoconjunctivitis sicca&#xD;
&#xD;
               -  Severe-exposure keratopathy&#xD;
&#xD;
               -  Disorders that would increase the risk of epithelium-related complications (e.g.,&#xD;
                  bullous keratopathy, aniridia, severe chemical burns, or neutrophilic keratitis)&#xD;
&#xD;
               -  Congenital abnormality (e.g., Fuch's dystrophy)&#xD;
&#xD;
               -  Abnormal slit-lamp examination using a vital dye (e.g., fluorescein or&#xD;
                  Bengal-Rose)&#xD;
&#xD;
               -  Abnormal corneal sensitivity test (e.g., Schirmer test or similar tear production&#xD;
                  test)&#xD;
&#xD;
          -  No concurrent ocular inflammation or infection&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated nonmelanoma skin&#xD;
             cancer or curatively treated carcinoma in situ of the cervix&#xD;
&#xD;
          -  No prior allergic reaction attributed to compounds of similar biological or chemical&#xD;
             composition to erlotinib&#xD;
&#xD;
          -  No other concurrent serious illness or medical condition that would preclude study&#xD;
&#xD;
          -  No prior significant neurologic or psychiatric disorder that would preclude study&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy for endometrial cancer&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No more than 1 prior hormonal therapy (progestational agent or aromatase inhibitor) in&#xD;
             the adjuvant or metastatic setting&#xD;
&#xD;
          -  At least 1 week since prior hormonal therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy (except for low-dose palliative&#xD;
             radiotherapy) and recovered&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 3 weeks since prior major surgery and recovered&#xD;
&#xD;
          -  No prior surgical procedures affecting absorption&#xD;
&#xD;
          -  No concurrent ophthalmic surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior EGFR-targeting therapies&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  Concurrent oral anticoagulants (e.g., warfarin) allowed provided there is increased&#xD;
             vigilance with respect to monitoring INR&#xD;
&#xD;
          -  Concurrent low molecular weight heparin allowed at investigator's discretion&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amit M. Oza, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tom Baker Cancer Center - Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Margaret and Charles Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingston Regional Cancer Centre</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Ontario-London Regional Cancer Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Notre- Dame du CHUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4L 2M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Oza AM, Eisenhauer EA, Elit L, Cutz JC, Sakurada A, Tsao MS, Hoskins PJ, Biagi J, Ghatage P, Mazurka J, Provencher D, Dore N, Dancey J, Fyles A. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol. 2008 Sep 10;26(26):4319-25. doi: 10.1200/JCO.2007.15.8808. Epub 2008 Jun 30.</citation>
    <PMID>18591547</PMID>
  </results_reference>
  <results_reference>
    <citation>Oza A, Elit L, Eisenhauer E, et al.: Phase II study of erlotinib (Tarceva, OSI 774) in women with recurrent or metastatic endometrial cancer -- NCIC IND.148. [Abstract] Clin Cancer Res 9 (Suppl): A-105, 6094s, 2003.</citation>
  </results_reference>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>February 14, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 24, 2014</last_update_submitted>
  <last_update_submitted_qc>January 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2014</last_update_posted>
  <keyword>stage IV endometrial carcinoma</keyword>
  <keyword>recurrent endometrial carcinoma</keyword>
  <keyword>endometrial adenocarcinoma</keyword>
  <keyword>endometrial adenosquamous cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

